Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
NetraMark Holdings ( (TSE:AIAI) ) has shared an announcement.
NetraMark Holdings has signed a contract with a leading biopharmaceutical company to apply its NetraAI platform to a Phase 3 clinical trial for a new psychiatric medicine. This collaboration highlights the increasing recognition of NetraMark’s AI technology in enhancing clinical trial success by identifying patient subpopulations and optimizing study outcomes. The agreement further extends NetraMark’s portfolio in neuroscience, oncology, and complex pain, demonstrating its capacity to deliver precision-trial insights that support drug development.
More about NetraMark Holdings
NetraMark Holdings Inc. is a leader in the development of Generative Artificial Intelligence and Machine Learning solutions for the pharmaceutical industry. The company offers a unique topology-based algorithm that segments patient data into subsets, enabling the use of various ML methods to transform data into intelligent insights. This allows NetraMark to work with smaller datasets and accurately classify patients for drug sensitivity and treatment efficacy.
YTD Price Performance: 19.61%
Average Trading Volume: 50,419
Technical Sentiment Signal: Buy
Current Market Cap: C$104.7M
For an in-depth examination of AIAI stock, go to TipRanks’ Overview page.